Nobelpharma Co Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Nobelpharma Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013961
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NobelPharma Co Ltd (NobelPharma) is a pharmaceutical company which develops medicines for rare diseases and unmet medical needs. The Company’s pipeline products include NPC-07, NPC-09, NPC-12, NPC-14, NPC-15, NPC-16, NPC-17 and NPC-18. It offers its products in the therapeutic areas of oncology, metabolic diseases; neurology, genetic disorders, women’s health and respiratory. NobelPharma conducts research and development of drugs under categories such as orphan drugs (drugs for rare medical conditions), off-label drug, medicines used for additional efficacy, and pediatric pharmaceuticals. The company has a distribution network which includes Nippon Shinyaku Co., Ltd., Fuji Pharma Co., Ltd and Eisai Co., Ltd. NobelPharma is headquartered in Tokyo, Japan.

Nobelpharma Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Nobelpharma Enters into Co-Promotion with ASKA Pharma and Medipal 10
Licensing Agreements 11
NobelPharma Enters into Licensing Agreement with Osaka University 11
NobelPharma Enters into Licensing Agreement with Savara 12
NobelPharma Enters into Licensing Agreement with Serendex Pharma 13
SRI International Enters into Licensing Agreement with Nobelpharma 14
Eisai To Enter Into Licensing Agreement With Nobelpharma For Antineoplastic Agent Gliadel 7.7Mg Implant 15
NobelPharma Enters Into Licensing Agreement With Pfizer For Sirolimus 16
NobelPharma Enters Into Licensing Agreement With Clinigen For Foscavir 17
Nobelpharma Co Ltd – Key Competitors 18
Nobelpharma Co Ltd – Key Employees 19
Nobelpharma Co Ltd – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Product Approvals 22
Nov 11, 2016: Ultragenyx Announces Withdrawal of Marketing Authorization Application for Aceneuramic Acid Prolonged Release (Ace-ER) in the European Union 22
Clinical Trials 23
Jul 27, 2016: Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Nobelpharma Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Nobelpharma Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Nobelpharma Enters into Co-Promotion with ASKA Pharma and Medipal 10
NobelPharma Enters into Licensing Agreement with Osaka University 11
NobelPharma Enters into Licensing Agreement with Savara 12
NobelPharma Enters into Licensing Agreement with Serendex Pharma 13
SRI International Enters into Licensing Agreement with Nobelpharma 14
Eisai To Enter Into Licensing Agreement With Nobelpharma For Antineoplastic Agent Gliadel 7.7Mg Implant 15
NobelPharma Enters Into Licensing Agreement With Pfizer For Sirolimus 16
NobelPharma Enters Into Licensing Agreement With Clinigen For Foscavir 17
Nobelpharma Co Ltd, Key Competitors 18
Nobelpharma Co Ltd, Key Employees 19
Nobelpharma Co Ltd, Other Locations 21

★海外企業調査レポート[Nobelpharma Co Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • China Suntien Green Energy Co Ltd (956):企業の財務・戦略的SWOT分析
    China Suntien Green Energy Co Ltd (956) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • BioMarin Pharmaceutical Inc (BMRN)-医療機器分野:企業M&A・提携分析
    Summary BioMarin Pharmaceutical Inc (BioMarin) is a biopharmaceutical company which develops and commercializes innovative pharmaceuticals that treat serious diseases and medical conditions. The company offers products for the treatment of various diseases such as Kyndrisa (drisapersen), Duchenne mu …
  • Globe Telecom Inc (GLO):企業の財務・戦略的SWOT分析
    Globe Telecom Inc (GLO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • PT AKR Corporindo Tbk (AKRA):企業の財務・戦略的SWOT分析
    Summary PT AKR Corporindo Tbk (AKR Corporindo), formerly PT Aneka Kimia Raya Tbk is a diversified company that distributes, trades, and markets basic chemicals, petroleum, and offers logistics and supply chain solutions. The company operates through its business divisions such as trading and distrib …
  • U.S. Stem Cell Inc (USRM):製薬・医療:M&Aディール及び事業提携情報
    Summary U.S. Stem Cell Inc (U.S. Stem Cell), formerly Bioheart, Inc, is a biotechnology company that focuses on the discovery, development and commercialization of cell based therapeutics products. The company repairs and replaces damaged or aged tissue, cells and organs and restoring their normal f …
  • Nuclear Power Corporation of India Ltd:電力:M&Aディール及び事業提携情報
    Summary Nuclear Power Corporation of India Ltd (NPCIL) designs, constructs, commissions and operates nuclear power reactors. The company operates atomic power plants and executes atomic power projects for electricity generation. It is administered by the Department of Atomic Energy (DAE), Government …
  • AES Gener SA (AESGENER):企業の財務・戦略的SWOT分析
    AES Gener SA (AESGENER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Tenneco Inc. (TEN):企業の財務・戦略的SWOT分析
    Tenneco Inc. (TEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • University of California Los Angeles-医療機器分野:企業M&A・提携分析
    Summary University of California Los Angeles (UCLA) a subsidiary of University of California is an educational service provider that offers undergraduate education, graduate, professional education and continuing education. The university’s services include support services, campus services, graduat …
  • Wilmar International Ltd (F34):企業の財務・戦略的SWOT分析
    Wilmar International Ltd (F34) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Forendo Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Forendo Pharma Ltd (Forendo Pharma) is a drug development company that concentrates on tissue specific regulation of sex hormone effects. The company’s product pipeline include fispemifene, which is in clinical phase II development and intended for the treatment of lower urinary tract sympto …
  • Army and Air Force Exchange Service:企業の戦略・SWOT・財務情報
    Army and Air Force Exchange Service - Strategy, SWOT and Corporate Finance Report Summary Army and Air Force Exchange Service - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Ebiquity plc (EBQ):企業の財務・戦略的SWOT分析
    Summary Ebiquity plc (Ebiquity) is a marketing and media consultancy service provider. The company’s services include marketing performance optimization services, media value measurement and market intelligence. Its business areas comprise data analytics and advanced analytics. Ebiquity’s data analy …
  • Ornim Inc:医療機器:M&Aディール及び事業提携情報
    Summary Ornim Inc (Ornim) is a medical device company that specializes in clinical research, development and distribution of medical devices in the field of tissue and cerebral blood flow and perfusion, among others. The company’s c-FLOW is a continuous non-invasive monitor of deep tissue blood flow …
  • BASF SE:企業の戦略・SWOT・財務情報
    BASF SE - Strategy, SWOT and Corporate Finance Report Summary BASF SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Gilead Sciences Inc (GILD):企業の財務・戦略的SWOT分析
    Gilead Sciences Inc (GILD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Butler National Corporation:企業の戦略・SWOT・財務分析
    Butler National Corporation - Strategy, SWOT and Corporate Finance Report Summary Butler National Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Moximed Inc:医療機器:M&Aディール及び事業提携情報
    Summary Moximed Inc (Moximed), formerly ExploraMed NC4, Inc. focuses to develop unicompartmental load absorber implants for patients with painful knee osteoarthritis (OA). The company provides Atlas Knee System, an implantable knee joint unloader which works as a shock absorber for pre-arthroplasty …
  • Jardine Cycle & Carriage Limited:企業の戦略・SWOT・財務情報
    Jardine Cycle & Carriage Limited - Strategy, SWOT and Corporate Finance Report Summary Jardine Cycle & Carriage Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Broadridge Financial Solutions, Inc.:企業の戦略・SWOT・財務分析
    Broadridge Financial Solutions, Inc. - Strategy, SWOT and Corporate Finance Report Summary Broadridge Financial Solutions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆